Table 3.
Type of harm expected from potentially serious drug-drug interaction for each index condition
Index condition | Cardiovascular* | Bleeding | Renal/potassium | Central nervous system | Other† | Total |
---|---|---|---|---|---|---|
Type 2 diabetes | ||||||
First line recommended drug | 3 | 3 | 2 | 0 | 12 | 20 |
Second line recommended drug | 54 | 11 | 18 | 1 | 29 | 113 |
Depression | ||||||
First line recommended drug | 1 | 9 | 0 | 7 | 2 | 19 |
Second line recommended drug | 10 | 13 | 0 | 27 | 20 | 70 |
Heart failure | ||||||
First line recommended drug | 15 | 0 | 4 | 0 | 2 | 21 |
Second line recommended drug | 17 | 34 | 17 | 0 | 22 | 90 |
*Includes effects on heart rate or rhythm or effects on blood pressure.
†Includes myopathy with statin treatment, or clinically relevant altered plasma concentration (for example, of digoxin, lithium, ciclosporin, or theophylline), which might require dose alteration or closer monitoring.